社区获得性肺炎住院患者的流感检测与治疗
本研究纳入2010至2015年美国179家医院收治的166,268例成人肺炎患者,评估流感检测频率、抗病毒治疗及结局。仅23.3%患者接受流感检测,流感季为28.9%;检测阳性者抗病毒治疗更多、抗菌药物疗程更短;入院首日使用奥司他韦与较低的14天院内死亡率、费用和住院时长相关。
要点
- 社区获得性肺炎住院患者中流感检测率低,流感季仅28.9%。
- 流感检测阳性者更常接受抗病毒治疗且抗菌药物疗程更短。
- 入院首日奥司他韦治疗与较低的14天院内死亡率和费用相关。
核心结论
- 多数社区获得性肺炎住院患者未接受流感检测,即使在流感季也是如此。
- 流感检测阳性与抗病毒治疗相关,早期抗病毒治疗与更好的临床结局相关。
研究设计与样本
- 回顾性队列研究,纳入2010至2015年美国179家医院收治的166,268例成人肺炎患者。
主要发现
- 166,268例患者中38,703例(23.3%)接受流感检测,其中11.5%阳性。
- 检测率从2010年15.4%升至2015年35.6%,流感季(10月至5月)为28.9%,6月至9月为8.2%。
- 流感阳性者较阴性者更常使用抗病毒药物、较少使用抗菌药物且疗程更短(5.3天 vs 6.4天;P < .001)。
- 入院首日使用奥司他韦(n=2,585)较延迟或未使用(n=1,742)的14天院内死亡率调整OR为0.75(95%CI 0.59-0.96)。
- 入院首日奥司他韦组费用调整均值比为0.88(95%CI 0.81-0.95),住院时长调整均值比为0.88(95%CI 0.84-0.93)。
关键数值与推荐
- 流感检测率:总体23.3%,流感季28.9%,非流感季8.2%。
- 流感阳性者抗菌药物疗程5.3天 vs 阴性者6.4天(P < .001)。
- 入院首日奥司他韦与14天院内死亡率调整OR 0.75(95%CI 0.59-0.96)相关。
临床怎么用
- 对社区获得性肺炎住院患者,尤其在流感季,应考虑更广泛地开展流感检测。
- 流感检测阳性者应尽早启动抗病毒治疗,可能缩短抗菌药物疗程并改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza is a leading cause of community-acquired pneumonia (CAP), and results of influenza tests can direct therapy. However, among adults hospitalized with CAP, little is known about the frequency and timing of influenza testing, treatment, and their associations with outcomes. RESEARCH QUESTION: In patients with CAP, is testing for influenza associated with antiviral treatment and shorter antibiotic courses, and is early treatment associated with better clinical outcomes? STUDY DESIGN AND METHODS: This study included adults admitted with pneumonia in 2010 to 2015 to 179 US hospitals contributing to the Premier database. We assessed influenza testing and compared antimicrobial utilization and the outcomes of test-positive, test-negative, and untested patients. Associations of early antiviral treatment (oseltamivir) with 14-day in-hospital mortality, hospital length of stay, and cost were studied. RESULTS: Among 166,268 patients with CAP, 38,703 (23.3%) were tested for influenza, of whom 11.5% tested positive. Testing increased from 15.4% to 35.6% from 2010 to 2015 and was 28.9% during flu season (October-May) vs 8.2% in June to September. Patients testing positive for influenza received antiviral agents more often and antibacterial agents less often and for shorter courses than patients testing negative (5.3 vs 6.4 days; P < .001). Influenza-positive patients receiving oseltamivir on hospital day 1 (n = 2,585) experienced lower 14-day in-hospital mortality (adjusted OR, 0.75; 95% CI, 0.59-0.96), lower costs (adjusted ratio of means, 0.88; 95% CI, 0.81-0.95), and shorter length of stay (adjusted ratio of means, 0.88; 95% CI, 0.84-0.93) vs patients receiving oseltamivir later or not at all (n = 1,742). INTERPRETATION: Even during flu season, most patients with CAP in this study went untested for influenza. A positive influenza test result was associated with antiviral treatment, and early treatment was associated with lower mortality, suggesting that more widespread testing might improve patient outcomes.
引用
- Deshpande, Klompas, Yu, et al. Influenza Testing and Treatment Among Patients Hospitalized With Community-Acquired Pneumonia. Chest. 2022. PMID: 35134384. doi:10.1016/j.chest.2022.01.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。